Dont fight the trend is an oft-used expression on Wall Street. It may be truer now than ever. Casting a dubious eye on what has amounted to a spectacular rise for equity markets since Donald Trump became president-elect in November is proving a costly enterprise.
Whether the advance for equities can sustain itself over the next month and into 2017 is anyones guess, but for now investors who have been reluctant to embrace the unabashed exuberance that has gripped stock investors over the past month are losing moneyfast.
day trading training: Scana Corporation(SCG)
- [By Lisa Levin]
In trading on Tuesday, utilities shares rose by just 0.1 percent. Meanwhile, top losers in the sector included Atlantic Power Corp (NYSE: AT), down 2 percent, and SCANA Corporation (NYSE: SCG) down 1 percent.
- [By Lisa Levin]
In trading on Friday, utilities shares were relative laggards, down on the day by about 0.32 percent. Meanwhile, top losers in the sector included Genie Energy Ltd (NYSE: GNE), down 3 percent, and SCANA Corporation (NYSE: SCG), down 3 percent.
- [By Lisa Levin]
In trading on Monday, utilities shares were relative laggards, down on the day by about 0.43 percent. Meanwhile, top losers in the sector included SCANA Corporation (NYSE: SCG), down 2 percent, and FirstEnergy Corp. (NYSE: FE), down 2 percent.
day trading training: Codexis, Inc.(CDXS)
- [By Maxx Chatsko]
While companies with lower-priced shares are often riskier than those with higher prices, some companies trading under $5 per share have intriguing potential. Investors searching for overlooked growth opportunities should consider industrial biotech BioAmber (NYSE:BIOA), pharmaceutical services company Codexis (NASDAQ:CDXS), and one-trick-pony biopharma Keryx Biopharmaceuticals (NASDAQ:KERX).
- [By Jim Robertson]
On Tuesday, our Under the Radar Moversnewsletter suggested taking a long/bullish position in small cap biocatalysts developer Codexis, Inc (NASDAQ: CDXS):
day trading training: Intercept Pharmaceuticals, Inc.(ICPT)
- [By Peter Graham]
Small cap liver biopharmaceutical stock Intercept Pharmaceuticals Inc (NASDAQ: ICPT) reportedQ2 2017 earnings before the market opened on Monday with both the top and bottom lines beating expectations plus the Companyreported that amid-stage clinical trial met its primary endpoint; but sharesended the day down13.26%. Intercept Pharmaceuticals recognized $30.4 million of net sales of Ocaliva for Q2 2017 versus $75k and a net loss of $86.6 million versus a net loss of $77.3 million. Ocaliva was approved by the U.S.FDA in May 2016 for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA or as monotherapy in adults unable to tolerate UDCA. As of June 30, 2017,the Companyhad cash, cash equivalents and investment securities available for sale of approximately $550.3 million versus$689.4 million as of December 31, 2016. The CEO commented:
day trading training: Stryker Corporation(SYK)
- [By Jayson Derrick]
Stryker Corporation (NYSE: SYK)’s stock fell nearly 5 percent on Aug. 23 as investors were troubled with the company’s recall announcement, Argus’ David Toung noted in a separate research report. But investors may want to consider taking advantage of the selloff as it represents a “favorable investment opportunity.”
day trading training: Federal-Mogul Holdings Corporation(FDML)
- [By Benzinga News Desk]
Mario Gabelli on Monday gained the upper hand in his battle to force Carl Icahn to sweeten his offer for a car-parts manufacturer. Icahn, who owns 82 percent of Federal-Mogul (NASDAQ: FDML), offered $9.25 a share for the remaining stake but fell way short after Gamco Investors boss Gabelli — who has a leading stake in Federal-Mogul — pressed for a higher price.
day trading training: QCR Holdings Inc.(QCRH)
- [By Keith Fitz-Gerald]
My favorite at the moment is QCR Holdings Inc. (NasdaqGM:QCRH).
Founded in 1993 and headquartered in Moline, IL, the bank has a strong regional lending base in Illinois and Iowa that should grow in line with the broader national economy. I particularly like the fact that the bank considers itself relationship-driven at a time when trust is in short supply.